Switching from Escitalopram to Bupropion for Erectile Dysfunction
Switch your patient to bupropion, as it has the lowest rate of sexual side effects among antidepressants and is specifically recommended for patients experiencing SSRI-induced sexual dysfunction. 1
Recommended Alternative Antidepressant
Bupropion is the clear choice here. The American College of Physicians guideline explicitly states that bupropion is associated with a lower rate of sexual adverse events than fluoxetine or sertraline, while paroxetine and escitalopram have higher rates of sexual dysfunction 1. This is further supported by research showing that nonserotonergic antidepressants like bupropion that primarily increase dopamine or norepinephrine are optimal for avoiding or managing antidepressant-associated sexual dysfunction 2, 3.
Other reasonable alternatives with lower sexual dysfunction risk include:
- Mirtazapine - demonstrated modestly lower risk compared to citalopram 4
- Nefazodone - shows less orgasm dysfunction in comparative studies 2
However, bupropion remains the first-line choice given the strongest evidence for minimal sexual side effects.
Tapering Strategy for Escitalopram 20mg
Do NOT stop escitalopram abruptly. The FDA label explicitly warns that stopping too quickly causes withdrawal symptoms including anxiety, irritability, mood changes, headache, sweating, nausea, dizziness, electric shock-like sensations, shaking, and confusion 5.
Conservative Taper (Recommended for Most Patients):
- Week 1-2: Reduce to 15mg daily
- Week 3-4: Reduce to 10mg daily
- Week 5-6: Reduce to 5mg daily
- Week 7: Stop
This follows the guideline recommendation of 25-50% dose reductions over 2-6 weeks for patients at standard risk 6. Escitalopram has moderate withdrawal risk - not as severe as paroxetine or venlafaxine, but still requires careful tapering 7, 6.
When to Start Bupropion:
Cross-taper approach: Start bupropion at low dose (150mg daily) when escitalopram reaches 10mg, then continue tapering escitalopram as outlined above. This minimizes the period without antidepressant coverage and reduces risk of depressive relapse 7.
Important safety note: Unlike MAOIs or certain other combinations, escitalopram and bupropion can be safely co-administered during the cross-taper since they work through different mechanisms 5.
Monitoring Requirements
The ACP guideline mandates assessment within 1-2 weeks of any medication change 1. Specifically monitor for:
- Withdrawal symptoms during taper (irritability, dizziness, paresthesias, mood instability)
- Depression relapse (worsening mood, anhedonia, suicidal ideation) - particularly critical given that response rates to antidepressants can be as low as 50% 1
- Sexual function improvement - should see benefit within 4-8 weeks on bupropion
- New side effects from bupropion (insomnia, agitation, seizure risk if predisposed)
If no adequate response to bupropion within 6-8 weeks, modify treatment per guideline recommendations 1.
Clinical Pitfalls to Avoid
Don't rush the taper. Patients at higher risk of withdrawal (longer duration on escitalopram, previous difficulty stopping antidepressants, anxiety disorders) may need even slower tapers over many weeks with smaller decrements 6.
Don't ignore baseline sexual function. The FDA label notes that sexual dysfunction occurs in over 50% of patients with major depression itself 5. Document current erectile function to distinguish medication effects from underlying depression.
Don't assume all sexual dysfunction will resolve. While switching to bupropion significantly improves sexual function in most patients, research shows that post-SSRI sexual dysfunction can rarely persist even after discontinuation 8.
Don't forget contraindications to bupropion: seizure disorders, eating disorders, abrupt alcohol/benzodiazepine discontinuation, and concurrent MAOI use are absolute contraindications.